Patent intelligence · US
US 6245362
Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication
Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medica…
Patent details — US 6245362
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 12, 2001
- Expiration
- Jun 7, 2021
- Claims
- 6
- CPC classes
- A61K, A61K36/38, A61P, A61P31/00
Quick answer
US 6245362 (Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication) is held by Dreluso Pharmazeutika Dr. Elten & Sohn GmbH. Status: expired. Granted Jun 12, 2001. Expires Jun 7, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K36/38, A61P, A61P31/00, A61P31/12
More from Dreluso Pharmazeutika Dr. Elten & Sohn GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Related coverage
Frequently asked questions
What is US patent 6245362?
US 6245362 (Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication) is held by Dreluso Pharmazeutika Dr. Elten & Sohn GmbH. Status: expired. Granted Jun 12, 2001. Expires Jun 7, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6245362?
Dreluso Pharmazeutika Dr. Elten & Sohn GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 6245362 expire?
Our index shows an expiration date of Jun 7, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.